822 A1A NORTH, PONTE VEDRA, FL
Market cap: $13.6M (2/09/2026)
Price: $5.81
Cadrenal Therapeutics Files Prospectus Supplement for $1.77M Stock Offering
Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)
Appoints Dr. Lee Golden to Board of Directors
Cadrenal Therapeutics Files Prospectus Supplement for $3.4M Stock Offering
Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Shareholder votes
Enhances Anticoagulation Pipeline Through Acquisition of eXIthera’s Portfolio of Factor XIa Inhibitors
Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Q3
Q2
Q1
FY 2024
FY 2023
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Notice of Exempt Offering of Securities
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload
SEC Staff Correspondence